Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

How sensitive is a prostate-specific antigen measurement? How sensitive does it need to be?

Bock JL, Klee GG.

Arch Pathol Lab Med. 2004 Mar;128(3):341-3.

PMID:
14987148
2.

Value of prostate-specific antigen as a tumor marker.

Wirth M, Manseck A, Heimbach D.

Eur Urol. 1993;24 Suppl 2:6-12.

PMID:
7505232
4.

Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.

Bastian PJ, Palapattu GS, Yegnasubramanian S, Lin X, Rogers CG, Mangold LA, Trock B, Eisenberger M, Partin AW, Nelson WG.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5361-7.

5.

Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay.

Ellis WJ, Vessella RL, Noteboom JL, Lange PH, Wolfert RL, Rittenhouse HG.

Urology. 1997 Oct;50(4):573-9.

PMID:
9338734
6.

Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.

Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR.

J Urol. 2003 Jan;169(1):157-63.

PMID:
12478126
8.

Markers and meaning of primary treatment failure.

Swindle PW, Kattan MW, Scardino PT.

Urol Clin North Am. 2003 May;30(2):377-401. Review.

PMID:
12735513
9.

Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men.

Bissonette EA, Fulmer BR, Petroni GR, Moul JW, Theodorescu D.

J Urol. 2001 Oct;166(4):1328-31; discussion 1331-2.

PMID:
11547067
10.

The use of 'ultrasensitive' prostate-specific antigen assays in the detection of biochemical recurrence after radical prostatectomy.

van Iersel MP, Thomas CM, Segers MF, Witjes WP, Debruyne FM, Oosterhof GO.

Br J Urol. 1996 Mar;77(3):418-22.

PMID:
8814849
11.

Prostate specific antigen in screening for recurrence following radical prostatectomy for localised prostatic cancer.

Bentvelsen FM, van den Ouden D, Schröder FH.

Br J Urol. 1993 Jul;72(1):88-91.

PMID:
7511971
12.

[Clinical surveillance after surgery for prostate cancer].

Guercio S, Terrone C, Scarpa RM.

Recenti Prog Med. 2003 Mar;94(3):110-3. Review. Italian.

PMID:
12677777
13.

Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L.

Yu H, Diamandis EP, Wong PY, Nam R, Trachtenberg J.

J Urol. 1997 Mar;157(3):913-8.

PMID:
9072598
14.

Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.

Haese A, Huland E, Graefen M, Hammerer P, Noldus J, Huland H.

J Urol. 1999 Apr;161(4):1206-11.

PMID:
10081870
15.

Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.

Roehrborn CG, Gregory A, McConnell JD, Sagalowsky AI, Wians FH Jr.

Urology. 1996 Dec;48(6A Suppl):23-32.

PMID:
8973696
16.

Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years.

Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC.

Urol Clin North Am. 1993 Nov;20(4):713-25.

PMID:
7505980
17.
18.
19.

Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.

Horninger W, Cheli CD, Babaian RJ, Fritsche HA, Lepor H, Taneja SS, Childs S, Stamey TA, Sokoll LJ, Chan DW, Brawer MK, Partin AW, Bartsch G.

Urology. 2002 Oct;60(4 Suppl 1):31-5.

PMID:
12384160
20.

Evaluation of prostAsure index in the detection of prostate cancer: a preliminary report.

Babaian RJ, Fritsche HA, Zhang Z, Zhang KH, Madyastha KR, Barnhill SD.

Urology. 1998 Jan;51(1):132-6.

PMID:
9457308

Supplemental Content

Support Center